Axsome Therapeutics’ (AXSM) “Outperform” Rating Reiterated at William Blair

William Blair restated their outperform rating on shares of Axsome Therapeutics (NASDAQ:AXSM) in a report published on Friday,RTT News reports.

Several other research firms have also recently weighed in on AXSM. Mizuho cut their target price on shares of Axsome Therapeutics from $124.00 to $122.00 and set an “outperform” rating for the company in a research note on Tuesday, December 31st. StockNews.com raised Axsome Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, November 20th. Needham & Company LLC restated a “buy” rating and set a $133.00 target price on shares of Axsome Therapeutics in a research report on Monday, January 13th. Royal Bank of Canada raised their price target on Axsome Therapeutics from $130.00 to $131.00 and gave the stock an “outperform” rating in a research report on Friday, October 4th. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $121.00 target price on shares of Axsome Therapeutics in a research report on Thursday, December 12th. One analyst has rated the stock with a hold rating and fourteen have issued a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $130.69.

Axsome Therapeutics Stock Performance

NASDAQ AXSM opened at $103.11 on Friday. The company has a quick ratio of 2.37, a current ratio of 2.44 and a debt-to-equity ratio of 1.97. Axsome Therapeutics has a twelve month low of $64.11 and a twelve month high of $105.00. The business has a 50-day moving average price of $92.64 and a 200-day moving average price of $90.15. The firm has a market cap of $5.00 billion, a price-to-earnings ratio of -15.79 and a beta of 1.04.

Axsome Therapeutics (NASDAQ:AXSM) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($1.34) earnings per share for the quarter, topping the consensus estimate of ($1.38) by $0.04. The business had revenue of $104.76 million during the quarter, compared to the consensus estimate of $98.71 million. Axsome Therapeutics had a negative return on equity of 158.36% and a negative net margin of 91.87%. During the same period in the prior year, the company posted ($1.32) EPS. As a group, equities research analysts predict that Axsome Therapeutics will post -4.73 EPS for the current fiscal year.

Institutional Trading of Axsome Therapeutics

A number of hedge funds have recently bought and sold shares of AXSM. Iron Triangle Partners LP purchased a new stake in shares of Axsome Therapeutics during the third quarter valued at about $22,671,000. FMR LLC grew its position in shares of Axsome Therapeutics by 20.6% in the 3rd quarter. FMR LLC now owns 1,088,087 shares of the company’s stock worth $97,786,000 after buying an additional 185,951 shares during the last quarter. abrdn plc raised its stake in shares of Axsome Therapeutics by 553.3% during the 4th quarter. abrdn plc now owns 72,179 shares of the company’s stock worth $6,107,000 after acquiring an additional 61,131 shares in the last quarter. Franklin Resources Inc. lifted its position in Axsome Therapeutics by 47.5% during the third quarter. Franklin Resources Inc. now owns 160,534 shares of the company’s stock valued at $13,713,000 after acquiring an additional 51,696 shares during the last quarter. Finally, Barclays PLC boosted its stake in Axsome Therapeutics by 279.6% in the third quarter. Barclays PLC now owns 61,785 shares of the company’s stock valued at $5,552,000 after acquiring an additional 45,509 shares in the last quarter. Hedge funds and other institutional investors own 81.49% of the company’s stock.

About Axsome Therapeutics

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.